Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53

被引:14
作者
Ferrarini, Alessandra [1 ]
Auteri-Kaczmarek, Agnes [2 ]
Pica, Alessia [3 ]
Boesch, Nemya [4 ]
Heinimann, Karl [4 ]
Schaefer, Stephan C. [5 ]
Vesnaver-Megalo, Sara [1 ]
Cina, Viviane [1 ]
Beckmann, Jacques S. [1 ]
Monnerat, Christian [1 ]
机构
[1] CHUV, Serv Genet Med, Lausanne, Switzerland
[2] CHUV, Fdn Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland
[3] CHUV, Serv Radiooncol, Lausanne, Switzerland
[4] Univ Childrens Hosp, Dept Biomed, Div Med Genet, Basel, Switzerland
[5] CHUV, Serv Pathol, Lausanne, Switzerland
关键词
Li-Fraumeni syndrome; Germline mutation TP53; De novo mutation; p.Arg213X; LI-FRAUMENI-SYNDROME; P53; FAMILIES; TUMORS; PREDISPOSITION; CRITERIA; DATABASE;
D O I
10.1007/s10689-010-9415-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report a 26-year-old female patient who was diagnosed within 4 years with chest sarcoma, lung adenocarcinoma, and breast cancer. While her family history was unremarkable, DNA sequencing of TP53 revealed a germline de novo non-sense mutation in exon 6 p.Arg213X. One year later, she further developed a contralateral ductal carcinoma in situ, and 18 months later a jaw osteosarcoma. This case illustrates the therapeutic pitfalls in the care of a young cancer patient with TP53 de novo germline mutations and the complications related to her first-line therapy. Suggestion is made to use the less stringent Chompret criteria for germline TP53 mutation screening. Our observation underlines the possibly negative effect of radiotherapy in generating second tumors in patients with a TP53 mutation. We also present a review of six previously reported cases, comparing their cancer phenotypes with those generally produced by TP53 mutations.
引用
收藏
页码:187 / 192
页数:6
相关论文
共 28 条
[1]   Identification of novel TP53 mutations in familial and sproadic cancer cases of German Swiss origin [J].
Bendig, I ;
Mohr, N ;
Kramer, F ;
Weber, BR .
CANCER GENETICS AND CYTOGENETICS, 2004, 154 (01) :22-26
[2]   Relative frequency and morphology of cancers in carriers of germline TP53 mutations [J].
Birch, JM ;
Alston, RD ;
McNally, RJQ ;
Evans, DGR ;
Kelsey, AM ;
Harris, M ;
Eden, OB ;
Varley, JM .
ONCOGENE, 2001, 20 (34) :4621-4628
[3]   A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].
Bond, GL ;
Hu, WW ;
Bond, EE ;
Robins, H ;
Lutzker, SG ;
Arva, NC ;
Bargonetti, J ;
Bartel, F ;
Taubert, H ;
Wuerl, P ;
Onel, K ;
Yip, L ;
Hwang, SJ ;
Strong, LC ;
Lozano, G ;
Levine, AJ .
CELL, 2004, 119 (05) :591-602
[4]   Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene [J].
Bougeard, G ;
Brugières, L ;
Chompret, A ;
Gesta, P ;
Charbonnier, F ;
Valent, A ;
Martin, C ;
Raux, G ;
Feunteun, J ;
Bressac-de Paillerets, B ;
Frébourg, T .
ONCOGENE, 2003, 22 (06) :840-846
[5]  
Boyle JM, 2002, RADIAT RES, V157, P158, DOI 10.1667/0033-7587(2002)157[0158:DCCIGI]2.0.CO
[6]  
2
[7]   Sensitivity and predictive value of criteria for p53 germline mutation screening [J].
Chompret, A ;
Abel, A ;
Stoppa-Lyonnet, D ;
Brugières, L ;
Pagès, S ;
Feunteun, J ;
Bonaïti-Pellié, C .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (01) :43-47
[8]  
FREBOURG T, 1995, AM J HUM GENET, V56, P608
[9]   Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations [J].
Gonzalez, Kelly D. ;
Noltner, Katie A. ;
Buzin, Carolyn H. ;
Gu, Dongqing ;
Wen-Fong, Cindy Y. ;
Nguyen, Vu Q. ;
Han, Jennifer H. ;
Lowstuter, Katrina ;
Longmate, Jeffrey ;
Sommer, Steve S. ;
Weitzel, Jeffrey N. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1250-1256
[10]   Multiple primary cancers in families with Li-Fraumeni syndrome [J].
Hisada, M ;
Garber, JE ;
Fung, CY ;
Fraumeni, JF ;
Li, FP .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08) :606-611